SAFETY OF SUBSEQUENT BIOLOGIC THERAPY IN RA PATIENTS WHO DISCONTINUED RITUXIMAB

被引：0
|
作者：
Genovese, Mark C. [1 ]
Breedveld, Ferdinand C. [2 ]
Emery, Paul [3 ]
Cohen, Stanley B. [4 ]
Keystone, Edward [5 ]
Matteson, Eric L. [6 ]
Burke, Laura [7 ]
Chai, Akiko [8 ]
Reiss, William [8 ]
Sweetser, Marianne [9 ]
Shaw, Tim [7 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Leiden Univ, Leiden, Netherlands
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Metroplex Clin Res Ctr, Dallas, TX USA
[5] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[6] Mayo Clin, Rochester, MN USA
[7] Roche, Prod Dev, Welwyn Garden City, Herts, England
[8] Genentech Inc, Stat, San Francisco, CA 94080 USA
[9] Biogen Idec Inc, Drug Safety, Cambridge, MA USA
来源：
RHEUMATOLOGY | 2011年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [21] Cardiovascular safety of biologic therapies for the treatment of RA
    Greenberg, Jeffrey D.
    Furer, Victoria
    Farkouh, Michael E.
    NATURE REVIEWS RHEUMATOLOGY, 2012, 8 (01) : 13 - 21
  • [22] Safety of biologic therapy
    Blonski, Wojciech
    Lichtenstein, Gary R.
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (06) : 769 - 796
  • [23] Risk of Infection Associated with Subsequent Biologic Use Following Rituximab-Results from a National RA Patient Registry.
    Harrold, Leslie R.
    Reed, George W.
    Karki, Chitra
    Magner, Robert
    Shewade, Ashwini
    John, Ani
    Kremer, Joel M.
    Greenberg, Jeffrey D.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S225 - S226
  • [24] Cardiovascular safety of biologic therapies for the treatment of RA
    Jeffrey D. Greenberg
    Victoria Furer
    Michael E. Farkouh
    Nature Reviews Rheumatology, 2012, 8 : 13 - 21
  • [25] Safety of TNF inhibitors (TNF-is) and non-biologic DMARDs in rheumatoid arthritis (RA) patients (pts) previously treated with Rituximab (RTX)
    Genovese, Mark
    van Vollenhoven, Ronald
    Breedveld, Ferdinand
    Emery, Paul
    Moreland, Larry
    Keystone, Edward
    Matteson, Eric
    Baptiste, Yvette
    Burke, Laura
    Reiss, William
    Sweetser, Marianne
    Shaw, Tim
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 44 - 44
  • [26] Sequential etanercept and rituximab therapy in patients with active RA-SERRA
    Brickmann, Kerstin S.
    Yazdani-Biuki, Babak J.
    Brezinschek, Ruth I.
    Graninger, Winfried B.
    Brezinschek, Hans-Peter
    ARTHRITIS AND RHEUMATISM, 2007, 56 (12): : 4278 - 4278
  • [27] EVALUATION OF BIOLOGIC THERAPY VERSUS TRIPLE DMARD THERAPY IN RA PATIENTS UNRESPONSIVE TO METHOTREXATE
    Vernice, Nicholas A.
    Reiss, Allison B.
    Renna, Heather A.
    DeLeon, Joshua
    Carsons, Steven
    Kasselman, Lora J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (03) : 697 - 697
  • [28] BIOLOGIC THERAPY WITH RITUXIMAB DECREASES PREVALENCE OF ANXIETY AND DEPRESSION IN RHEUMATOID ARTHRITIS PATIENTS
    Gaisin, I.
    Ivanova, L.
    Maximov, N.
    Vedekhina, A.
    Yurk, D.
    Garaeva, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 983 - 983
  • [29] AN ASSESSMENT OF THE SERIOUS INFECTION RATE IN RITUXIMAB-TREATED RHEUMATOID ARTHRITIS (RA) PATIENTS WHO SUBSEQUENTLY RECEIVED OTHER BIOLOGIC THERAPIES: A FOLLOW-UP FROM RITUXIMAB CLINICAL TRIALS
    Genovese, Mark C.
    Breedveld, Ferdinand C.
    Emery, Paul
    Cohen, Stanley B.
    Keystone, Edward C.
    Matteson, Eric L.
    Burke, Laura S.
    Chai, Akiko
    Reiss, William G.
    Sweetser, Marianne T.
    Shaw, Tim M.
    RHEUMATOLOGY, 2010, 49 : I4 - I4
  • [30] Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis
    Kuttipurath Kandi Roshique
    Vinod Ravindran
    Clinical Rheumatology, 2015, 34 : 1289 - 1292
12345